L3VLUP
ProSign in

CYRX in the 13F filings

Cryoport Inc · CUSIP 229050307

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q1 2020
Quarter end
31 Dec 2021
the date the book describes
Filed
14 Feb 2022
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2021 and Q4 2021; 1 listed it in both
Shares listed
49,706
combined, among listed positions
Reported value
$2.9m
combined, at the quarter end

Managers listing CYRX in Q4 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Bridgewater Associates LP49,706$2.9munder 0.1%New+6,59114 Feb 2022 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2021 to Q4 2021, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q2 2021 to 1 in Q2 2026

Tracked managers listing it, at least.

01232020202120222026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CYRX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20161$46kn.a.n.a.
Q2 20181$1.6mn.a.n.a.
Q3 20181$2.0mn.a.n.a.
Q2 20191$440kn.a.n.a.
Q3 20191$582kn.a.n.a.
Q1 20201$203kn.a.n.a.
Q3 20203$66mn.a.n.a.
Q4 20203$50mn.a.n.a.
Q1 20211$58mn.a.n.a.
Q2 20212$63mn.a.n.a.
Q3 20212$16mn.a.n.a.
Q4 20211$2.9mn.a.n.a.
Q1 20222$9.1mn.a.n.a.
Q3 20221$801kn.a.n.a.
Q4 20251$3.0m125
Q1 20261$6.2m109
Q2 20261$20m175

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CYRX and LLY →CYRX and JNJ →CYRX and VRTX →Choose a stock to compare with CYRX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CYRX, latest filings →Back to the 13F Explorer →